Cardiology Group Names Finerenone Preferred MRA Treatment

The American College of Cardiology recommends finerenone as the preferred mineralocorticoid receptor antagonist for heart failure.

Updated on Oct. 16, 2026 in Heart Disease

Isometric editorial illustration of a glass medical vial and a metallic heart model, representing clinical cardiac treatment guidelines. — The American College of Cardiology now recommends finerenone as the preferred mineralocorticoid receptor antagonist for treating patients with heart failure. AI Illustration. Upload story photo >

Live Poll

Do you trust your primary care provider to correctly identify and treat emerging chronic heart conditions?

The American College of Cardiology has released an expert consensus decision pathway identifying finerenone as the preferred mineralocorticoid receptor antagonist (MRA). This guidance aims to optimize care for patients suffering from heart failure with preserved ejection fraction, the most common heart failure phenotype in the United States.

Why it matters

Finerenone is being prioritized because it offers a more favorable adverse effect profile compared to spironolactone. The update seeks to improve detection and management of heart failure with preserved ejection fraction, which is frequently overlooked in primary care and rural medical settings.

Finerenone is approved for patients with an estimated glomerular filtration rate as low as 25, while spironolactone is restricted to rates of 30 or higher. This shift recognizes the broader kidney function range allowed for finerenone treatment.

The players

American College of Cardiology

This is a professional medical association and licensing body that provides guidelines and education for cardiovascular specialists.

The details

Pharmacists are now tasked with utilizing chronic disease management workflows to better identify patients and optimize guideline-directed medical therapy. This approach is intended to bridge gaps in treatment for patients with heart failure with preserved ejection fraction.

The expert consensus pathway was published on October 16, 2026.

Health Landscape

This decision marks an evolution in the American College of Cardiology expert consensus decision pathway for heart failure management. By preferring nonsteroidal MRAs, the field moves toward treatments with more favorable side effect profiles compared to traditional therapies.

Patients currently taking spironolactone may see their doctors transition them to finerenone if their clinical profile warrants the change to a drug with a better side effect profile. Individuals managing heart failure should discuss these latest guidelines with their primary care provider to determine if this therapy is appropriate for their renal function.

The takeaway

Patients should note that newer nonsteroidal medications are increasingly becoming the standard of care for heart failure due to improved safety profiles. Regular monitoring of glomerular filtration rates remains a critical component for those managing heart failure treatments.